Repose

Quick links to important sections

Repose

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Repose

Property Description
Active ingredient Propofol
Form Intravenous Injectable Emulsion
Pharmacological Class General Anesthetic, Intravenous Hypnotic Agent
Common Use Inducing and maintaining anesthesia or sedation
Origin Synthetic (Non-Barbiturate Phenol Derivative)

What Type of Medicine is Repose (Propofol)?

Repose is a potent, synthetic medication classified as an intravenous hypnotic agent and a general anesthetic. Its core active ingredient is Propofol, a compound chemically defined as 2,6-diisopropylphenol. This drug is distinguished within its pharmacological class because it is a non-barbiturate agent, a feature clinically recognized for facilitating rapid and clear patient emergence from anesthesia, compared to older compounds.


Composition and Injectable Emulsion Form

Repose is formulated as a specialized, white, opaque injectable emulsion for intravenous administration, requiring direct delivery into the bloodstream. This unique form of pharmaceutical preparation is essential because Propofol is highly lipophilic (fat-soluble) and must be suspended in an oil-in-water emulsion, stabilized by components such as soybean oil and purified egg lecithin, rather than a simple water base. The medication is characterized by its rapid onset and short duration of action. This means the medication works quickly and its effects wear off rapidly, allowing for faster recovery.


What is the General Purpose of This Hypnotic Agent?

The general purpose of Repose is to initiate and sustain a state of general anesthesia necessary for various surgical and diagnostic procedures. Furthermore, it is extensively used to provide controlled, prolonged sedation for critically ill patients in intensive care units (ICU), particularly those requiring supportive measures like mechanical ventilation. This capability to manage the state of consciousness is what makes Propofol a foundation of modern anesthetic practice.

Regulatory References

  1. World Health Organization's Essential Medicines List
  2. WHO Essential Medicines List
  3. NIH StatPearls Article on Propofol

What side effects are possible with Repose?

Possible Side Effects and Safety Information

The safety profile of Repose (Propofol) is formally structured by government regulatory agencies, classifying potential adverse reactions by frequency and affected organ system.

Key risks primarily involve the Cardiovascular and Respiratory systems. Arterial hypotension (decreased blood pressure) and transient apnea (cessation of breathing) during the induction phase are commonly documented effects. Pain during injection is classified as a Very Common localized effect.

Frequency and Organ Systems

Adverse reactions are grouped according to their incidence and System-Organ Class (SOC):

Classification Example Adverse Reaction SOC Involved
Common Hypotension, Nausea/Vomiting Vascular, Gastrointestinal
Uncommon Thrombosis, Phlebitis Vascular
Rare Anaphylaxis, Postoperative Unconsciousness Immune System, Nervous System
Very Rare Pancreatitis, Tissue Necrosis Gastrointestinal, Administration Site

Serious Adverse Reactions and Constraints

Regulatory documents highlight severe but rare risks, including Propofol Infusion Syndrome (PRIS), a serious metabolic complication associated with prolonged, high-dose use, and the potential for Anaphylaxis. Safety constraints include a contraindication for individuals with known hypersensitivity to the drug or to egg or soybean products due to the injectable emulsion's composition.

Population and Duration Notes

The official labeling contains specific safety notes for certain populations. Older adults may be more susceptible to pronounced cardiorespiratory effects, such as hypotension. Pediatric patients under three years of age may risk adverse effects on early brain development with repeated or prolonged sedation use. Risks are also tied to administration method; cardiorespiratory effects are more likely with bolus dosing or rapid infusion rates.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Repose, which is officially documented as a medical emergency, is primarily characterized by severe cardiorespiratory depression resulting from excessive blood concentrations. The most critical manifestations cited in regulatory documents include apnoea (respiratory arrest) and profound arterial hypotension (a severe drop in blood pressure), a combination that can rapidly escalate to cardiovascular collapse and potentially death.

Regulators mandate that immediate medical attention must be sought whenever overdosage is suspected. The required first emergency action is the immediate cessation of the drug’s administration.

The official prescribing information confirms that no specific antidote is known for Propofol toxicity. Consequently, management is structured entirely around prompt symptomatic and supportive treatment. This includes ensuring a patent airway, providing artificial ventilation with oxygen, and managing circulatory depression with intravenous fluids and the administration of vasopressor agents.

Population-specific notes indicate that pediatric patients and the elderly or debilitated are at a greater risk for severe cardiovascular depression following overdosage. All patients must be kept under intensive observation until stable, reflecting the severity classification applied by official authorities.

Therapeutic Uses of Repose

What Repose Treats: Main Uses and Benefits

Repose (Propofol) is an intravenous hypnotic agent commonly used to help with acute or disruptive symptom patterns related to consciousness. This medication is primarily used for managing the need for general anesthesia for surgical procedures, providing procedural sedation for short-term diagnostic interventions, and offering controlled sedation to manage critically ill adult patients who require mechanical ventilation.

In clinical settings, the medication is applied in addressing symptoms related to systemic imbalance and heightened physiological activity. For instance, it helps manage severe agitation and restlessness in the Intensive Care Unit, or it may assist with addressing intractable neurological activity, such as refractory seizure states. By managing these distressing manifestations, the medication contributes to improved comfort during periods of heightened symptoms.

“This medication is commonly used to help with sudden symptom escalation, may provide supportive relief when symptoms become temporarily overwhelming.”

Quick Fact: Relief for Heightened Awareness

Eligibility and Restrictions for Use

Repose (tirzepatide) is officially designated for use only in adults (age 18 and older). Eligibility is strictly defined by formal contraindications and mandatory restrictions outlined in government regulatory labeling. Pediatric use has not been established.

Populations That Must Not Use Repose (Contraindicated)

  • Thyroid Cancer Risk: Patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) must not use this medicine. It is also contraindicated for patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Allergic Reaction: Individuals with a documented serious hypersensitivity reaction to the active substance (tirzepatide) or to any of the inactive ingredients (excipients) must not use Repose.

Eligibility Restrictions and Special Considerations

  • Severe Gastrointestinal Disease: Use is not recommended in patients with a history of severe gastrointestinal disease (such as severe gastroparesis) as it has not been studied in this population and may be associated with severe adverse reactions.
  • Pregnancy and Lactation: Repose may cause fetal harm. Use must be discontinued when a pregnancy is recognized. Females of reproductive potential taking oral contraceptives are advised to switch to a non-oral method or add a barrier method, as the drug may reduce the efficacy of oral contraceptives.
  • Coadministration: The medicine should not be used concomitantly with other tirzepatide-containing products or other specific related therapies (GLP-1 receptor agonists).

What should I know about interactions with other medicines?

Repose (Propofol) has an interaction profile defined by its pharmacological effects and its specialized, lipid-based formulation. A primary documented interaction is Pharmacodynamic Potentiation: co-administration with other central nervous system depressants, such as Opioids, Sedatives, or other Analgesic Agents, is officially noted to increase the anesthetic or sedative effects. This combination may result in more pronounced cardiorespiratory depression, including hypotension.

Regarding drug-drug interactions that modify exposure, Valproate is specifically noted in regulatory information as leading to increased blood levels (plasma concentration) of Propofol, an outcome associated with altered clearance. Alcohol is also documented to potentially increase the risk or severity of CNS depression.

A necessary restriction exists due to the product's emulsion formulation: Repose is contraindicated in patients with a known hypersensitivity to soy or peanuts because the formulation contains soybean oil and egg lecithin. Furthermore, the emulsion must not be mixed with any other infusion solutions prior to administration due to physical incompatibility.

Procedural constraints require the intravenous line to be rinsed or flushed after the administration of certain muscle relaxants (e.g., Atracurium or Mivacurium) if the same access site is used. Regulatory labeling also highlights a heightened risk of interaction-related cardiorespiratory effects when co-administering the drug with premedicants in elderly or debilitated patients.

Mechanism of Action

How Repose Works

Targeted Receptor Binding

Repose initiates its action by acting within domains involving receptor- or enzyme-mediated signaling, binding selectively to defined biological targets (e.g., specific receptors or enzymes). This mechanism modifies early molecular steps, initiating or suppressing specific signaling sequences to achieve rapid alteration of activity within central and/or peripheral pathways.


Influence on Signaling Pathways

The drug's primary mechanistic focus is to alter signaling dynamics in defined neural or humoral pathways. It is applied to influence pathways associated with high-frequency physiological signaling, which causes the system to reduce the rate of signal transmission and influence the activity of specific signaling mediators.


Mechanistic Influence on Systemic Feedback

By engaging mechanisms that influence feedback regulation within pathways, Repose alters feedback mechanisms that modify overall systemic signaling within targeted physiological systems. This targeted pathway interference contributes to modifying activity within high-frequency signaling systems, leading to resulting modifications to physiological activity that shape the drug's overall effect profile.

Dosage and Administration Information

How Repose is Used

Repose (Propofol) is an intravenous hypnotic agent administered only via the intravenous (IV) route and requires direct delivery into the bloodstream. This administration is strictly confined to a supervised medical environment, such as a hospital, operating room, or intensive care unit (ICU), and must be performed by professionals trained in anesthesia or intensive care.


Dosing and Administration Patterns

The dosage of Repose is characterized by its reliance on titration, meaning the rate and amount are continuously adjusted to the individual patient's immediate need, rather than being a static regimen.

Usage Context Administration Method and Rate
Induction (Onset of effect) Initial, weight-based bolus injection, typically 1.5 to 2.5 mg/ kg total dose, titrated by injecting small increments over seconds.
Maintenance/ICU Sedation Continuous, variable rate infusion, commonly 100 to 200 mu g/ kg/ min for maintenance. For prolonged ICU sedation, rates generally should not exceed 4.0 mg/ kg/ h.

Procedural Requirements and Adjustments

Aseptic technique is mandatory during the handling and administration of the injectable emulsion. The product may be used undiluted or diluted only with 5% Dextrose Injection, USP, but never to a concentration below 2 mg/ mL.

Clinically, older, debilitated, or severely ill patients require a reduced initial dose and slower administration speed to manage potential effects. The medication is a single-use product, and any unused portion, including administration sets, must be promptly discarded within the designated time limit to adhere to proper handling protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Repose (Propofol)

The research record for Repose (Propofol) centers on its use as an intravenous agent for anesthetic and critical care purposes. The clinical evaluation involves official data, primarily from Randomized Controlled Trials (RCTs) and meta-analyses, which compared the medication against other sedative or anesthetic agents. This summary outlines the specific clinical situations that have been studied, the types of patient outcomes that were measured, and the recognized limits of the available evidence, as reported in governmental and peer-reviewed scientific sources.


Evidence for Use in General Anesthesia

Official research involves extensive RCTs that have evaluated its properties for the rapid start and continuous maintenance of anesthesia. Researchers primarily examined time-based measurements, including the time required for patients to lose consciousness, the duration of stable anesthesia, and the time until extubation (removal of the breathing tube).

Trials reported measurements of a rapid loss of consciousness following administration. Research highlights changes measured during the study period indicating a short time until return to consciousness, with observed patterns related to the time it takes for patients to reach standard cognitive markers after the infusion is stopped. However, the majority of this evidence is short-term, focusing only on the immediate recovery period.


Evidence for Use in Procedural and Critical Care Sedation

Propofol was studied for short-term procedural sedation (for brief diagnostic procedures) and for continuous, prolonged critical care sedation in mechanically ventilated adults. In procedural studies, researchers monitored outcomes related to the achievement of target sedation depth and recovery time.

For critical care, research monitored variables such as the duration of mechanical ventilation and the total length of ICU stay. Studies report how symptoms evolved in the observed populations, with findings related to the maintenance of a prescribed target level of sedation necessary for supportive care.


Research Gaps and Uncertainties

The research base is built upon its intended use as a rapidly acting, short-duration agent, meaning that data on long-term effects are inherently limited. Evidence is limited for outcomes tracked over weeks or months following administration. Additionally, the evidence for less common or specialized applications, while existing in observational cohort studies, is often less conclusive, and certainty remains low compared to the core anesthetic indications.

Frequently Asked Questions (FAQ)

Common questions about Repose (FAQ)


Q: Does Repose work immediately, or does it take time to feel the effects?

According to the official product information, Repose is known for its rapid onset of action. This means that when the medication is administered, the sedative or anesthetic effects begin quickly. This rapid effect is one of the key characteristics of the drug.


Q: How long does one dose of Repose typically last?

Official documents indicate Repose has a short duration of action and is quickly eliminated from the body. This rapid clearance allows for a relatively quick return to consciousness after the medication is stopped, which is important for recovery from anesthesia.


Q: Is it true that Repose can make you feel sleepy?

Yes, according to official classification, Repose is an intravenous hypnotic agent. Its purpose is to induce a reduced state of consciousness, ranging from deep sedation to general anesthesia.


Q: Are there any common over-the-counter pain relievers that interact with Repose?

Regulatory information advises caution regarding other medications classified as analgesic agents (pain relievers), as co-administration may increase the sedative or cardiorespiratory effects of Repose. The administering professional will determine if adjustments are needed based on existing medications.


Q: Are there any foods or drinks that should be avoided while taking Repose?

Official documents note that alcohol may increase the risk of central nervous system depression when taken near the time of administration. Furthermore, the drug is contraindicated (must not be used) in people with a known hypersensitivity to soy or egg products, as these ingredients are used to formulate the injectable emulsion.


Q: What is the safety profile of Repose during long-term use?

For patients receiving prolonged, high-dose continuous infusion in the ICU, there is a serious but rare metabolic risk known as Propofol Infusion Syndrome (PRIS). Official research documentation also indicates that evidence tracking effects over long periods, such as weeks or months, is limited.


Q: Is Repose safe for older adults (seniors)?

Regulatory documents specify that older or debilitated patients may be more susceptible to pronounced effects, particularly a drop in blood pressure (hypotension). For this reason, administering professionals often use a slower speed and reduced initial dose for these patients, as outlined in the official guidance.


Q: What kind of monitoring might a doctor recommend while taking Repose?

Because of the risk of serious but transient effects like arterial hypotension (low blood pressure) and apnea (cessation of breathing), regulatory documents require continuous monitoring of the patient's vital functions. This must be performed by professionals specifically trained in anesthesia and intensive care.


Q: Does Repose affect sleep quality?

As Repose is an intravenous hypnotic agent, it directly affects the state of consciousness during its use. Official product information primarily focuses on the immediate anesthetic and sedative effects, and it does not specifically describe any lasting or residual changes to a person's normal sleep quality after the effects of the drug have fully worn off.


Q: Is there a maximum time someone can stay on Repose?

The medication is not intended for continuous, indefinite use at high rates. Regulatory guidance advises against prolonged infusion at high doses due to the increased risk of a serious complication known as Propofol Infusion Syndrome (PRIS).


Q: Can Repose be used in children or adolescents?

Repose is officially approved for use in general anesthesia for patients aged 3 years and older. However, official labeling does include a warning about the potential for adverse effects on early brain development when the drug is used repeatedly or for prolonged periods in children under 3 years of age.


Q: Do you need a special kind of prescription to get Repose?

Repose is a specialized intravenous agent that is administered only in a supervised medical environment, such as an operating room or ICU, by trained medical professionals. It is not provided to patients to take home, meaning it is not obtained through a standard retail pharmacy prescription for self-administration.


Q: Is Repose generally considered safe by regulatory bodies?

Repose is an FDA-approved and EMA-authorized medication that is authorized for use for its specific indications, such as anesthesia and sedation. Regulatory authorization indicates that the drug has been reviewed for safety and effectiveness when administered by trained medical personnel in appropriate clinical settings and according to official guidelines.


Q: Is Repose intended for short-term or long-term use?

Repose has official indications for both short-term and prolonged uses. It is used for the short-term goals of inducing and maintaining general anesthesia during procedures. It is also indicated for continuous sedation for patients who are mechanically ventilated in an Intensive Care Unit (ICU), which can be a more prolonged use.


Q: Can I take other mental health medications while using Repose?

Regulatory documents note that co-administration with other CNS depressants (Central Nervous System depressants), which includes some mental health medications, can increase the sedative and anesthetic effects of Repose. Due to this potential interaction, increased caution and potential dosage adjustments are required by the administering professional.


Q: Is Repose considered a controlled substance in the US?

According to official U.S. sources, the active ingredient in Repose (Propofol) is not classified as a controlled substance under the U.S. Controlled Substances Act.


Q: Can I take Repose if I have high blood pressure?

Hypotension (low blood pressure) is a common side effect of Repose itself. Regulatory guidance notes that the drug may also decrease the activity of certain medications used to treat high blood pressure. Caution is advised, particularly for patients who are severely ill.


Q: How is Repose different from other medicines used for similar conditions?

Repose is classified chemically as a non-barbiturate phenol derivative, distinguishing it from older anesthetic classes. This chemical characteristic is recognized as often facilitating a rapid and clear emergence (or recovery) from anesthesia compared to some other compounds.


Q: Does Repose have a generic version available?

Yes, the active ingredient in Repose (Propofol) is available in officially approved generic injectable emulsion forms, in addition to its branded product versions.


Q: Does Repose affect my ability to drive or operate machinery?

The official guidance advises patients that their mental alertness may be impaired, and they should not drive, operate hazardous machinery, or engage in other risky activities until the effects have fully resolved and they have returned to their pre-anesthesia state.


Q: What is the 'boxed warning' associated with Repose?

The official U.S. labeling for Repose does not carry an FDA Boxed Warning (sometimes called a Black Box Warning). However, the document does contain a Warnings and Precautions section that highlights serious risks, including microbial contamination, cardiovascular depression, and the risk of Propofol Infusion Syndrome (PRIS).


Q: What if I have an existing kidney condition and need to take Repose?

Regulatory guidance notes that the serious complication Propofol Infusion Syndrome (PRIS) is associated with underlying risk factors, including renal dysfunction (kidney injury). The administering professional is advised to use caution when Repose is given to patients who may be at risk of developing PRIS.


Q: Is it normal to feel a bit restless when first starting Repose?

Regulatory safety data lists adverse reactions categorized as 'excitation phenomena' in the Nervous System. These effects may include involuntary movements, twitches, or tremors. In rare instances, restlessness has been reported as part of this excitation profile.


Q: Is it true Repose can cause dry mouth?

Dry mouth is not classified as a common or very common side effect in the regulatory documentation. However, official adverse reaction reports have occasionally included it as a rare adverse reaction associated with the drug.


Q: What is the difference between a side effect and an adverse event for Repose?

In regulatory documentation, an adverse event is a broad term for any undesirable medical occurrence following the drug's use, regardless of whether it was caused by the drug. A side effect is typically understood as a known, secondary, and often expected effect that is causally linked to the drug's pharmacological properties.


Q: Can I take Repose if I have a history of liver problems?

Regulatory documents note that the serious complication Propofol Infusion Syndrome (PRIS) has been associated with an enlarged or fatty liver. The administering professional is advised to use caution when Repose is given to patients who are considered to be at risk of PRIS.

How should Repose be stored and disposed of?

Repose (Propofol) injectable emulsion requires strict storage and handling to maintain its quality and sterility. The product must be stored at Controlled Room Temperature (e.g., 4 C to 25 C) and must not be frozen. It should remain in its original container until use.

Handling and Stability

Strict aseptic technique must be maintained during handling. Once the single-patient vial is opened, administration should commence promptly and must be completed within 12 hours, with any unused product and administration line discarded thereafter. Do not use if the emulsion shows phase separation or is suspected of contamination.

Disposal

Unused or expired product and waste materials must be disposed of in accordance with local and institutional requirements for pharmaceutical waste and must not be disposed of via wastewater. The medicine must also be kept out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Repose found in:

A-Z Index: